Media
Read our latest media releases, news and stories to find out what we’re doing and where.
Read our latest media releases, news and stories to find out what we’re doing and where.
Centrient Pharmaceuticals, the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the signing of an agreement for the acquisition of Astral SteriTech Private Limited, a leading international manufacturer specialised in sterile antibiotic injectable finished dosage forms. With the acquisition of Astral SteriTech, Centrient strengthens its position as the global business-to-business industry leader in beta-lactam antibiotics.
read moreAt Centrient Pharmaceuticals, our aim is always total transparency and integrity. With the help of our new Centrient SpeakUp procedure, in place since November 2020, our employees, business partners and other stakeholders can report any potential concerns regarding (possible) misconduct in the strictest confidence.
read moreSustainability matters a great deal to everyone at Centrient Pharmaceuticals, it is core to our mission and essential in shaping our authentic and purposeful culture.
read moreCentrient Pharmaceuticals introduced a new Centrient Code of Conduct in 2020.
read moreCentrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals, is announcing that Karl Rotthier has decided to step down as CEO after having built a highly successful company over the last ten years and managing a smooth transition to the new ownership under Bain Capital.
read moreDoubling our API capacity to meet the growing demand
read moreOur clear product recall procedures enable immediate, effective responses to issues.
read moreOur pharmacovigilance system is helping to ensure safer use of medicines.
read moreDoubling our API capacity to meet the growing demand for high-quality Atorvastatin and Rosuvastatin
read more